|
USA-823106-LibrariesPublic 公司名录
|
公司新闻:
- FDA expands approval of Modernas RSV vaccine to some adults under age . . .
The U S Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) vaccine on Thursday to include adults under the age of 60 at increased risk of the disease
- Moderna Receives U. S. FDA Approval for RSV Vaccine, mRESVIA, in Adults . . .
Expanded indication builds on existing U S FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA ACCESS Newswire June 12, 2025 Moderna, Inc (NASDAQ:MRNA) today announced that the U S Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company's respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease (LRTD
- FDA expands approval for Modernas RSV vaccine - The Hill
The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include individuals 18-59 years of age who are at increased risk for severe illness from
- US FDA Approves Expanded Use of Modernas RSV Vaccine for At-Risk Adults
The FDA approved mRESVIA in adults aged 60 or older last year, but with a lower efficacy label indicating the shot was 79% effective at preventing at least two symptoms of RSV, such as cough and
- FDA approves expanded use of Moderna’s RSV shot, but . . . - MSN
The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to 59 years old who are at increased risk for severe illness from
- Moderna’s mRNA RSV vaccine wins expanded FDA approval for younger . . .
The expanded approval now includes individuals aged 18 to 59 who are at risk of RSV This approval was supported by results from Moderna’s Phase III study (NCT06067230), which demonstrated the vaccine’s immune response worked just as well in this age group compared to the existing approved age group of 60 years and older
- Moderna wins FDA OK to widen use of RSV vaccine
The FDA cleared Moderna's RSV shot for use in certain adults between the ages of 18 and 59 on June 12, 2025 The Food and Drug Administration has approved wider use of Moderna’s respiratory syncytial virus vaccine in a boost for a company that’s been negatively impacted by the recent leadership changes atop U S public health agencies
- FDA Approves Modernas RSV Vaccine, MRESVIA, For Younger Adults
The vaccine was generally well-tolerated, and the most commonly reported solicited adverse reactions were injection site pain, fatigue, headache, myalgia and arthralgia MRNA closed Thursday's
- Moderna Receives U. S. FDA Approval for RSV Vaccine, mRESVIA, in Adults . . .
Expanded indication builds on existing U S FDA approval of mRESVIA for adults aged 60 and older CAMBRIDGE, MA ACCESS Newswire June 12, 2025 Moderna, Inc (NASDAQ:MRNA) today announced that
- FDA nod for Moderna’s RSV Vaccine, mRESVIA for younger adults
US mRNA specialist Moderna today announced that the US Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), the company's respiratory syncytial virus (RSV) vaccine, for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18-59 years of age who are at increased risk for disease
|
|